Nilkamal Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2025.
NILKAMAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nilkamal's board, at its May 14, 2025 meeting, approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, carrying an unmodified auditor opinion from S R B C & Co LLP. On a standalone basis, FY25 revenue from operations rose to Rs. 3,23,931.79 lakhs from Rs. 3,13,410.96 lakhs in FY24, but net profit fell to Rs. 9,127.08 lakhs (vs Rs. 10,731.22 lakhs), and EPS slipped to Rs. 61.16 from Rs. 71.91. Q4 standalone revenue grew ~7% YoY to Rs. 87,658.76 lakhs while PAT was nearly flat at Rs. 3,476.45 lakhs. The board recommended a final dividend of Rs. 20 (200%) per share, subject to shareholder approval at the July 18, 2025 AGM. It also approved a Rs. 4 crore acquisition of the healthcare business (including IP, contracts, employees and goodwill) from Imedfurns Private Limited, payable over 4 years, and the continuation of Mr. Sharad V. Parekh as Chairman for another 4 years.
Mixed signals for shareholders: revenue growth was healthy but FY25 profits and EPS declined around 15% YoY, suggesting margin pressure despite top-line expansion. The 200% dividend reaffirms a shareholder-friendly payout policy, while the small healthcare foray signals modest diversification beyond the core furniture and material handling business.